Robin Howard W

Nektar Therapeutics

President & CEO, Director

Avg. Two Year Performance

(62%) Avg. Purchase Return (27%) Compound

(12%) Avg. Sale Return (6%) Compound

Holdings: 832.49K shares

Last Three Months: 23-Aug-24 -- 22-Nov-24

0 Net Amount

Buy:	0	--
Sell:	0	--

Sentiment

Company Sentiment

Drug Delivery

Drugs

Two Year Chart

23-Nov-22 -- 22-Nov-24

Price ($)

Two Year Stock Price Chart

Sentiment

Company Sentiment

Most Recent Insider Transactions